These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1778327)

  • 21. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
    Kuno-Sakai H; Kimura M; Watanabe H
    Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination.
    Olin P; Hallander HO; Gustafsson L; Barreto L; Podda A
    Dev Biol Stand; 1998; 95():211-20. PubMed ID: 9855434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine.
    Rendi-Wagner P; Kundi M; Mikolasek A; Vécsei A; Frühwirth M; Kollaritsch H
    Vaccine; 2006 Aug; 24(33-34):5960-5. PubMed ID: 16757063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on acellular pertussis vaccine efficacy through September 11, 1988.
    Olin P; Romanus V; Storsaeter J
    Tokai J Exp Clin Med; 1988; 13 Suppl():55-7. PubMed ID: 3078810
    [No Abstract]   [Full Text] [Related]  

  • 25. Invasive bacterial infections during an efficacy trial of acellular pertussis vaccines--implications for future surveillance in pertussis vaccine programmes.
    Olin P; Romanus V; Storsaeter J
    Tokai J Exp Clin Med; 1988; 13 Suppl():143-4. PubMed ID: 3078803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination.
    Rappuoli R
    Infect Agents Dis; 1996 Jan; 5(1):21-8. PubMed ID: 8789596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effectiveness of whole-cell pertussis vaccines.
    Plotkin SA
    Dev Biol Stand; 1997; 89():171-4. PubMed ID: 9272348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Time for booster doses against whooping cough for 10-year-old children].
    Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
    Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 33. Composition of acellular pertussis and combination vaccines: a general review.
    Jadhav SS; Gairola S
    Biologicals; 1999 Jun; 27(2):105-10. PubMed ID: 10600195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model.
    David S; van Furth R; Mooi FR
    Vaccine; 2004 May; 22(15-16):1892-8. PubMed ID: 15121300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.
    Hviid A; Stellfeld M; Andersen PH; Wohlfahrt J; Melbye M
    Vaccine; 2004 Sep; 22(27-28):3530-4. PubMed ID: 15315832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of pertussis vaccine efficacy using a correlates of protection model.
    Kohberger RC; Jemiolo D; Noriega F
    Vaccine; 2008 Jun; 26(27-28):3516-21. PubMed ID: 18495303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance.
    Storsaeter J; Olin P
    Vaccine; 1992; 10(3):142-4. PubMed ID: 1557928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pertussis antibodies, protection, and vaccine efficacy after household exposure.
    Storsaeter J; Blackwelder WC; Hallander HO
    Am J Dis Child; 1992 Feb; 146(2):167-72. PubMed ID: 1733145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction to the International Symposium on Pertussis Evaluation and Research on Acellular Pertussis Vaccines.
    Oya A
    Dev Biol Stand; 1991; 73():3-4. PubMed ID: 1778323
    [No Abstract]   [Full Text] [Related]  

  • 40. Acellular pertussis vaccines--a question of efficacy.
    Olin P
    J Hosp Infect; 1995 Jun; 30 Suppl():503-7. PubMed ID: 7560990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.